Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALGeneric

ERYC 125

ERYTHROMYCIN

Standard Dose
125MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued

Key Takeaways

  • Primary indication: Marketing status: Discontinued
  • Approval overview ERYC 125 is listed in Drugs@FDA under application 062648 (ANDA).
  • Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG Sponsor PARKE DAVIS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview ERYC 125 is listed in Drugs@FDA under application 062648 (ANDA). Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG Sponsor PARKE DAVIS Submission history See approval history documents.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.